Sierra Oncology Inc (SRRA)

Overview

Sierra Oncology, Inc. is a biopharmaceutical company dedicated to the late-stage research, development, and commercialization of innovative therapeutic solutions for patients suffering from blood disorders and various types of cancer. As a key player in the biopharmaceutical industry, the firm has a focused vision towards creating impactful treatments that enhance the quality of life for patients. The primary drug candidate under Sierra's umbrella is momelotinib, which represents a significant advancement in targeted therapy. Initially founded as ProNAi Therapeutics, Inc. in 2003, the company rebranded to Sierra Oncology, Inc. in January 2017 and is currently headquartered in San Mateo, California. The company has been operating as a subsidiary of GSK plc since July 1, 2022, further expanding its capabilities and resources through strategic partnerships.

Products and Services

• Momelotinib: An orally administered, selective inhibitor targeting Janus kinase 1 (JAK1), JAK2, and Activin A receptor type 1 (ACVR1). This drug candidate is pivotal for patients with myelofibrosis and other malignancies, aiming to provide new hope through precise targeting of disease mechanisms.
• SRA515: A selective bromodomain-containing protein 4 inhibitor, which plays a critical role in epigenetic regulation. This product is being investigated for its potential to disrupt cancer cell proliferation and survival, thus representing a promising avenue in cancer therapy.
• SRA737: An orally bioavailable small molecule designed to inhibit Checkpoint kinase 1. By interfering with the cell cycle and DNA damage response, SRA737 may enhance the efficacy of existing cancer therapies, addressing treatment-resistant cancer populations.
• SRA141: A small molecule kinase inhibitor targeting Cdc7, developed in partnership with Carna Biosciences, Inc. This innovative drug aims to hinder cancer cell division, providing a strategic approach to cancer treatment in conjunction with other therapies.